CEO of eXoZymes to Present at ThinkEquity's Annual Investor Conference

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) announced that CEO Michael Heltzen will present at the ThinkEquity Annual Investor Conference on October 30, 2025 at the Mandarin Oriental Hotel in New York City.

The 30-minute presentation is scheduled for 8:00–8:30 AM in Lotus Suite East and will describe eXoZymes' AI-engineered enzyme platform—branded exozymes—which the company says enables cell-free, scalable biomanufacturing for natural products and potential pharmaceuticals. Management highlights a natural product called NCT that is reported to be showing promising results in improving metabolic health.

ThinkEquity expects over 750 institutional and high-net-worth investors and more than 85 selected companies to attend the conference.

LOS ANGELES, CALIFORNIA / ACCESS Newswire / October 23, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced that CEO, Michael Heltzen, will present at the 2025 ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York City.

CEO of eXoZymes, Michael Heltzen, states, "Most investors already know that - compared to the number of dollars invested - synthetic biology unfortunately has very little to show for it because it never scaled commercially. That's why we have introduced the next generation of biomanufacturing - a groundbreaking new way of making chemicals by using AI to convert enzymes to function cell-free in a bioreactor. Our initial focus with this paradigm shifting platform is natural products with the potential to become pharmaceuticals. Leading this strategy with a natural product called NCT which is showing very promising results in improving metabolic health."

eXoZymes has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods - or natural extraction - with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Heltzen continues, "By using the ingenuity of biology, coupled with AI, and combining it with the scalability of chemical engineering - we have solved the scaling bottleneck of synthetic biology. As such, we believe eXoZymes is positioned to lead the 4th industrial revolution at the intersection of biology and technology, which we're excited to detail to investors at ThinkEquity's conference next week!"

Organized by ThinkEquity LLC, the conference will showcase more than 85 carefully selected companies across biotechnology, artificial intelligence, crypto, mining, and other high-growth sectors. Over 750 institutional and high-net-worth investors are expected to attend.

Michael Heltzen will be presenting eXoZymes to investors on Thursday, October 30, at 8:00-8:30 AM in the Lotus Suite East at the Mandarin Oriental Hotel.

About ThinkEquity LLC

ThinkEquity is a boutique investment bank created by experienced professionals that have worked together for over a decade, collectively financing over $50 billion of public and private capital raises, restructurings, and mergers and acquisitions.

For more information about ThinkEquity, visit https://www.think-equity.com

About eXoZymes

Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce chemical compounds, enabling the company's partners to upgrade traditional petro-chemical production methods with a new commercially scalable, sustainable, and eco-friendly alternative: exozymes.

Exozymes are advanced enzymes enhanced through AI and bioengineering to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform biomass into essential chemicals, medicines, and biofuels.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more on exozymes.com

eXoZymes Safe Harbor

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact

Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

SOURCE: eXoZymes

View the original press release on ACCESS Newswire

FAQ

When will eXoZymes (EXOZ) present at the ThinkEquity conference on October 30, 2025?

CEO Michael Heltzen will present on October 30, 2025 from 8:00–8:30 AM in Lotus Suite East at the Mandarin Oriental Hotel.

What will eXoZymes (EXOZ) discuss at the ThinkEquity 2025 investor presentation?

Management will outline its AI-engineered enzyme platform exozymes and early results for the natural product NCT aimed at improving metabolic health.

How can investors attend or follow eXoZymes (EXOZ) presentation at ThinkEquity on October 30, 2025?

Investors attending the conference can join the Lotus Suite East session; remote access details are not provided in the announcement.

What is eXoZymes' (EXOZ) core technology highlighted for investors on October 30, 2025?

The company emphasizes an AI-driven platform that converts enzymes to function cell-free in bioreactors to produce natural products and chemicals.

Who is expected to attend ThinkEquity's 2025 conference where EXOZ presents?

The conference expects over 750 institutional and high-net-worth investors and more than 85 selected companies across biotech and other growth sectors.